BioCentury
ARTICLE | Clinical News

Athenex's actinic keratosis ointment meets in pair of Phase III trials

August 10, 2018 12:20 AM UTC

Athenex Inc. (NASDAQ:ATNX) said KX2-391 (KX-01) met the primary endpoint of improving the proportion of patients who achieved complete clearance of actinic keratosis (AK) lesions within the face or scalp treatment areas at day 57 vs. placebo in a pair of Phase III trials (p<0.0001 for both). The double-blind, U.S. KX-AK-003 and KX-AK-004 trials enrolled a total of 702 patients with AK on the face or scalp to receive vehicle ointment or once-daily KX2-391 for five days.

Data are to be presented at a medical meeting, and Athenex plans to meet with FDA to discuss next steps. KX2-391 is a topical 1% ointment of a small molecule inhibitor of Src tyrosine kinase signaling and tubulin polymerization...

BCIQ Company Profiles

Almirall S.A.

Athenex Inc.

BCIQ Target Profiles

Src

Tubulin polymerase